Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Could everyday hospital equipment be the next defence against counterfeit medicines?
MedTech
Could everyday hospital equipment be the next defence against counterfeit medicines?
A new study suggests the equipment already found in hospitals worldwide could offer a front line against fake vaccines and insulin.   23 February 2026
BioNTech fires shots at Moderna's next-generation vaccine
Americas
BioNTech fires shots at Moderna's next-generation vaccine
The German biotech claims the newly approved vaccine infringes its mRNA patent, deepening an already complex feud with billions of dollars at stake.   20 February 2026
Natera targets ex-employee over mass file download before rival move
Americas
Natera targets ex-employee over mass file download before rival move
The genetic testing firm claims that a former oncology specialist stole hundreds of confidential files in the dead of night, days before moving to a competitor.   19 February 2026
Careers
Hogan Lovells makes senior public and administrative hire in Italy
A lawyer with three decades of experience across energy, technology, life sciences, sports and media has joined the firm's Global Regulatory & IP practice in Milan.   18 February 2026
Regulation & Industry
Danaher moves to acquire Masimo in $9.9bn deal
The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.   18 February 2026
Asia-Pacific
Generic rival blocked as AZ defends diabetes stronghold
With a UK defeat still fresh, the Swedish-British drugmaker has secured breathing room in Australia—but a validity battle and key question of patent law looms at trial.   17 February 2026
Careers
Norton Rose Fulbright expands pharma and biotech disputes team
The firm recruits two Cooley partners with expertise in Hatch-Waxman, BPCIA, trade secrets, and competitor versus competitor patent litigation.   13 February 2026
Pharma
The curtain closes on three major drug disputes
Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.   11 February 2026
Americas
Novartis takes aim at Tafinlar generic in latest suit
The Swiss pharma giant moves to protect patents on its billion-dollar cancer therapy following an ANDA filing by a Canadian generics manufacturer.   9 February 2026
Careers
Wilson Sonsini senior counsel moves to a rival firm
The New York-based partner will advise biotech, pharma, and technology clients on patent prosecution, IP strategy and venture-backed transactions.   6 February 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.